A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	Recruiting	Phase 1 / Phase 2	2026-10-09		NCT07266428

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ottimo Pharma Limited	1

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ankara Bilkent City Hospital	Ankara	Turkey (Türkiye)	25
Ankara Oncology Training and Research Hospital	Ankara	Turkey (Türkiye)	2
Auckland City Hospital	Auckland	New Zealand	68
Cancer Research SA	Adelaide	Australia	3
Centro Gaucho Integrado	Porto Alegre	Brazil	1
Chris O'Brien Lifehouse	Camperdown	Australia	9
Dana-Farber Cancer Institute	Boston	United States	626
Fundación Jiménez Díaz	Madrid	Spain	11
Hospital de Santa-Maria-Centro Hospitalar Lisboa Norte (CHLN)	Lisbon	Portugal	1
Instituto do Cancer do Estado de São Paulo (ICESP)	São Paulo	Brazil	1
Linear Clinical Research	Nedlands	Australia	6
NEXT Oncology Barcelona	Barcelona	Spain	4
NEXT Oncology Madrid	Madrid	Spain	6
Oncosite - Centro de Pesquisa Clinica Em Oncologia	Ijuí	Brazil	8
Oncostar	São Paulo	Brazil	1
South Texas Accelerated Research Therapeutics (START)	San Antonio	United States	8
South Texas Accelerated Research Therapeutics (START) Midwest	Grand Rapids	United States	9
START - Rioja	Rioja	Spain	1
START Dublin Early Phase Clinical Trials Unit	Dublin	Ireland	2
START Mountain Region	West Valley City	United States	46
Yale Cancer Center	New Haven	United States	31

Clinical trials